These 29-Year-Olds’ AI Chatbot For Scheduling Doctor Visits Is Now Worth $1.2 Billion

Scheduling a doctor’s appointment is a universally dreaded ordeal—long hold times, endless form-filling, and frustrating back-and-forth. A startup founded by two 29-year-olds has turned that pain point into a $1.2 billion business. Assort Health’s AI-powered chatbot automates the entire booking process, and its latest venture round—the third in just 14 months—pushes its valuation into the billion-dollar club, signaling growing investor confidence in practical healthcare AI applications.

Assort Health provides an AI chatbot that handles end‑to‑end appointment scheduling for medical practices. Patients interact with the chatbot via phone, text, or web, and the system integrates directly with clinic calendars, automatically updating availability and sending reminders. For physicians, the tool reduces administrative burden and no‑show rates; for patients, it cuts wait times and eliminates the frustration of phone tag. The company’s rapid growth reflects the healthcare industry’s desperate need for digital solutions that improve both the patient and provider experience.

The startup was founded in 2021 by two 29-year-old entrepreneurs who experienced the scheduling nightmare firsthand. Their solution leverages natural‑language processing and machine learning to understand patient requests, verify insurance eligibility, and confirm appointments without human intervention. Each interaction trains the model further, making the system more efficient over time. Assort Health now serves hundreds of medical practices across the United States, from primary care to specialty clinics.

The latest funding round, whose investors include prominent venture firms focused on health tech, brings the company’s total equity raised to an undisclosed sum—though the $1.2 billion valuation speaks to the market’s appetite for AI that delivers measurable cost savings. In an industry where administrative costs account for roughly 25% of total healthcare spending, even modest efficiency gains offer massive returns. Analysts point out that Assort Health’s model is sticky: once a practice integrates the chatbot, switching costs become high, providing a moat against competitors.

But the rise of such technology also raises questions about data privacy and the digital divide. Older patients or those with limited tech literacy may still need human alternatives, and the chatbot must handle sensitive health data under strict regulations like HIPAA. Assort Health says it encrypts all patient information and allows clinics to maintain a hybrid human‑AI workflow for complex cases.

Looking ahead, Assort Health plans to expand into telemedicine scheduling, insurance pre‑authorization, and even AI‑driven patient triage. With billions in venture capital flowing into generative and conversational AI, the company is well positioned to capture a slice of the $400 billion global healthcare administrative market. The next milestone: proving that its chatbot can scale beyond the US and integrate seamlessly with electronic health records from major vendors like Epic and Cerner. If it succeeds, that $1.2 billion valuation may only be the beginning.